A NON-INVASIVE BREATH TEST FOR LUNG CANCER. 

Lung cancer is the leading cause of cancer deaths among both men and women. Each year, more people die of lung cancer than from colon, breast, and prostate cancer combined.

Today, most lung cancers are diagnosed at late stage. With Respiragen testing, early detected patients can benefit from curative surgery or radiation therapy with improved survival rates.

Respiragen testing offers a new path to stay ahead of lung cancer.

• 100% patient-safe test that requires only a breath sample; using patented mRNA breath analytics technology.

• Delivers fast and actionable results to support early stage curative intervention and post-treatment recurrence monitoring.

• Identifies changes in gene expression ratios - one of the earliest hallmarks of cancer in asymptomatic subjects.

• Clinically validated, highly sensitive and lung cancer specific means clear results and fewer potential errors.